Law
Intellectual Property Rights vs. Access to Essential Medicines
Quick fact
During the HIV/AIDS crisis, life-saving antiretroviral drugs cost around $10,000 per person per year, but by 2001, low-cost generic versions produced in India were available for under $350 a year, driving a dramatic expansion of treatment access.
Why this is interesting
Imagine a life-saving drug priced at $1,000 a month when the ingredients cost only $1—why can't someone simply make a cheaper copy? Who holds the right to decide who lives or dies?
Read the full explanation
Understanding Intellectual Property Rights vs. Access to Essential Medicines
Think of a patent as a temporary monopoly granted by a government to a drug company. In exchange for publicly disclosing the drug's formula, the company gets the exclusive right to sell it, usually for about 20 years. This means no one else can legally make a generic copy. With no competition, the company can set a high price, which covers research costs and generates profit. But this monopoly also means that many people—especially in low-income countries—cannot afford the drug. International trade rules, especially the TRIPS Agreement, require all member countries to recognize patents, but they also allow exceptions called 'flexibilities' that help countries protect public health, such as when a country issues a compulsory license to override a patent in an emergency.
A deeper explanation
The underlying rationale for patent protection is to incentivize innovation: if companies knew their drugs could be freely copied immediately, they would have little reason to invest the enormous sums needed for research and development. However, this incentive comes at a social cost because medicine is a fundamental human need. The global regime, led by the World Trade Organization's TRIPS Agreement, mandates patents on medicines, but it also recognizes public health concerns. The 2001 Doha Declaration reaffirmed countries' right to use flexibilities, including compulsory licensing and parallel importation, to meet public health needs. When exercising that flexibility, a government can authorize a local company to produce a generic version while paying the patent holder a small royalty. This balance is imperfect: countries like India use these flexibilities to supply generic drugs globally, while wealthier countries hesitate, fearing political pressure. The system thus continuously juggles the competing values of innovation and access.